Features

Viewpoints

Multitumor “Exceptional Responder” Program in Australia Seeks to Gain Clinical Context

By

Christina Bennett, MS

Publish Date November 12, 2019

The first multitumor exceptional responder program in Australia is under way, adding to the growing worldwide effort to identify patient DNA changes and biomarkers of response.

FDA Proposal Threatens Transparency on Cancer Drug Safety and Efficacy

By

Christina Bennett, MS

Publish Date November 4, 2019

FDA documents have been a trove of information for researchers, leading to new insights about the safety and efficacy of a drug. An FDA proposal could end that.

From the Advisory Board

We Can Treat Hodgkin’s Lymphoma Like Melanoma?

By

Isabel Cunningham, MD

Publish Date September 3, 2015

Isabel Cunningham, MD, Cancer Therapy Advisor Advisory Board member, weighs in on recent discoveries in the treatment of hematologic cancers.

Slideshows

BAVENCIO (avelumab) for Merkel Cell Carcinoma

IMLYGIC (talimogene laherparepvec) for Melanoma

Features

When Patient-Reported Outcomes Could Pose Risks

By

Julia Faith Sklar

Publish Date December 6, 2019

During a recent conference on quality of life in patients with cancer, FDA-affiliated researchers debunked a notion about biases — but raised some concerns about PROs.

How to Help Patients With Cancer Find Trustworthy Information Online

By

Amber Dance, PhD

Publish Date December 4, 2019

Patients may find misinformation on websites or social media forums, but doctors can help by recommending reliable sources.

Multinational Consensus Panel Confirms Benefits of Exercise, Updates Recommendations for Cancer Survivors

By

Bette Weinstein Kaplan

Publish Date December 4, 2019

The American College of Sports Medicine reconvened the ACSM Roundtable to update its guidelines for prescribing exercise for patients and survivors of cancers.